US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Cross Timbers Royalty

10.34

+0.18001.77%

Pre-market: 11.351.01+9.77%04:33 EDT

Volume:82.95K

Turnover:849.75K

Market Cap:62.04M

PE:10.93

High:10.89

Open:10.01

Low:10.01

Close:10.16

Loading ...

Overview Company News Filings

KEYTRUDA® (pembrolizumab) as Perioperative Treatment With Standard of Care (SOC) Adjuvant Therapy Significantly Improved Event-Free Survival Compared to SOC Alone in Patients With Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma

Why Cross Timbers Royalty Trust (CRT) Is Losing This Week

PennyMac Mortgage Investment Trust Reports First Quarter 2025 Results

FDA Approves WiSE® System, World's First and Only Leadless Left Ventricular Endocardial Pacing (LVEP) Device for CRT

Press Release: CROSS TIMBERS ROYALTY TRUST DECLARES APRIL CASH DISTRIBUTION

Which ASX company has just secured FDA approval?

Australian Shares Rise Amidst Temporary Reprieve for Electronic Tariffs; EBR Systems Receives US FDA Approval for Heart Failure Treatment Device

MT Newswires Live

U.S. Food and Drug Administration Approves Opdivo® (nivolumab) plus Yervoy® (ipilimumab) as a Treatment for Patients with Previously Untreated Microsatellite Instability-High or Mismatch Repair Deficient Unresectable or Metastatic Colorectal Cancer1

IMFINZI® (durvalumab) approved in the US as first and only perioperative immunotherapy for patients with muscle-invasive bladder cancer

Bristol Myers Squibb Receives Positive CHMP Opinion for the Subcutaneous Formulation of Opdivo® (nivolumab) Across Multiple Solid Tumor Indications

New study results reinforce TAGRISSO® (osimertinib) as the backbone therapy for EGFR-mutated lung cancer across stages and settings

EBR Systems Advances Towards FDA Approval and Market Launch of WiSE CRT System

Press Release: CROSS TIMBERS ROYALTY TRUST DECLARES MARCH CASH DISTRIBUTION

AZN's Imfinzi Gets EU Nod for Limited-Stage Small-Cell Lung Cancer

SMART Trial two-year data continues to demonstrate superior valve performance for Evolut TAVR™ system in small annulus patients

IMFINZI® (durvalumab)-based regimen demonstrated statistically significant and clinically meaningful improvement in event-free survival in resectable early-stage gastric and gastroesophageal junction cancers

Bristol Myers Squibb Receives European Commission Approval for Opdivo® (nivolumab) plus Yervoy® (ipilimumab) for the First-Line Treatment of Adult Patients with Unresectable or Advanced Hepatocellular Carcinoma

Press Release: MCCOY GLOBAL ANNOUNCES FOURTH QUARTER AND YEAR END 2024 RESULTS AND INCREASE TO ITS QUARTERLY DIVIDEND

Ekso Bionics Reports Fourth Quarter and Full-Year 2024 Financial Results

Press Release: Robotic Telesurgery Data from Collaboration with Corewell Health(TM) Accepted for Presentation at the Cardiovascular Research Technologies Annual Meeting

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/CRT/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"CRT","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CRT\",,,,,undefined,":{"symbol":"CRT","market":"US","secType":"STK","nameCN":"Cross Timbers Royalty","latestPrice":10.34,"timestamp":1745611200000,"preClose":10.16,"halted":0,"volume":82946,"hourTrading":{"tag":"盘前","latestPrice":11.35,"preClose":10.34,"latestTime":"04:33 EDT","volume":1,"amount":11.35,"timestamp":1745829214989},"delay":0,"floatShares":5999764,"shares":6000000,"eps":0.946303,"marketStatus":"Pre-Mkt","change":0.18,"latestTime":"04-28 06:56:09 EDT","open":10.01,"high":10.894,"low":10.01,"amount":849748.0939239999,"amplitude":0.087008,"askPrice":13.74,"askSize":100,"bidPrice":9.2,"bidSize":100,"shortable":3,"etf":0,"ttmEps":0.946303,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1745847000000},"marketStatusCode":1,"adr":0,"adrRate":0,"listingDate":699253200000,"exchange":"NYSE","adjPreClose":10.34,"dividendRate":0.091519,"preHourTrading":{"tag":"盘前","latestPrice":11.35,"preClose":10.34,"latestTime":"04:33 EDT","volume":1,"amount":11.35,"timestamp":1745829214989},"postHourTrading":{"tag":"盘后","latestPrice":10.34,"preClose":10.34,"latestTime":"16:39 EDT","volume":66,"amount":681.26,"timestamp":1745613569812},"volumeRatio":2.2241707541167215},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CRT\",,,,,undefined,":{"symbol":"CRT","floatShares":5999764,"roa":"85.14%","roe":"222.44%","lyrEps":0.946303,"volumeRatio":2.2241707541167215,"shares":6000000,"dividePrice":0.946303,"high":10.894,"amplitude":0.087008,"preClose":10.16,"low":10.01,"week52Low":8.8801,"pbRate":"25.50","psRate":"9.37","week52High":14.6799,"institutionHeld":0.0363,"latestPrice":10.34,"eps":0.946303,"divideRate":0.091519,"volume":82946,"delay":0,"ttmEps":0.946303,"open":10.01,"prevYearClose":9.9,"prevWeekClose":10.34,"prevMonthClose":13.17,"prevQuarterClose":13.17,"fiveDayClose":10.32,"twentyDayClose":11.76,"sixtyDayClose":11},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"CRT\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2530548354","title":"KEYTRUDA® (pembrolizumab) as Perioperative Treatment With Standard of Care (SOC) Adjuvant Therapy Significantly Improved Event-Free Survival Compared to SOC Alone in Patients With Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2530548354","media":"Business Wire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530548354?lang=en_us&edition=fundamental","pubTime":"2025-04-28 00:00","pubTimestamp":1745769600,"startTime":"0","endTime":"0","summary":"KEYNOTE-689 marks the first positive trial in more than two decades for patients with resected locally advanced head and neck squamous cell carcinoma . Results to be presented at American Association for Cancer Research  Annual Meeting 2025 during a Plenary Session and included in official meeting press program. \"As the first positive trial in over two decades for patients with resectable, locally advanced head and neck squamous cell carcinoma, the presentation of these landmark results marks an important moment for these patients and those who care for them,\" said Dr. Ravindra Uppaluri, the study’s co-principal investigator, director of Head and Neck Surgical Oncology, Brigham and Women’s Hospital and Dana-Farber","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/keytruda-pembrolizumab-perioperative-treatment-standard-160000135.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0320765489.SGD","LU0320765646.SGD","LU0054578231.USD","SG9999014567.USD","LU1066051225.USD","BTC","LU1861220033.SGD","AEIS","LU2361044865.SGD","OS","SMP","HCC","ITT","LU0208291251.USD","IE00B7SZL793.SGD","LU0861579265.USD","BK4097","IE00BZ199S13.USD","LU1934455194.USD","LU2106854487.HKD","RCC","CRT","LU1430594728.SGD","SOC","ALT","BK4605","LU0265550946.USD","LU0289739699.SGD","MRK","IE0009355771.USD","BCG","BK4533","IE00BLSP4452.SGD","SG9999015358.SGD","SGXZ57979304.SGD","BK4161","LU1037948541.HKD","LU2361044949.HKD","SG9999001440.SGD","LU1854103824.USD","IE00BLSP4239.USD","HSCT","DM","ON","CPS","LU2023250843.SGD","BK4135","LU2298322129.HKD","CRC","LU1162221912.USD"],"gpt_icon":0},{"id":"2529938083","title":"Why Cross Timbers Royalty Trust (CRT) Is Losing This Week","url":"https://stock-news.laohu8.com/highlight/detail?id=2529938083","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529938083?lang=en_us&edition=fundamental","pubTime":"2025-04-24 19:24","pubTimestamp":1745493859,"startTime":"0","endTime":"0","summary":"We recently published a list ofEnergy Stocks that are Losing This Week. In this article, we are going to take a look at where Cross Timbers Royalty Trust  stands against other energy stocks that are crashing this week.After a promising start to the year, the overall energy sector has fallen by almost 5.5% since the beginning of 2025. However, it still beats the 9.9% decline suffered by the wider market. The major reason behind this downturn is the plunge in global crude oil price, caused by the continued uncertainty surrounding the ongoing tariff war, the prospects of an economic slowdown, and the recent decision by OPEC+ to increase supply in May.Cross Timbers Royalty Trust  declared its April cash dividend of $0.0321 per share last week, significantly lower than the $0.1567 per share cash distribution it announced in March. The company revealed that its oil sales volume declined by 36.8% from the previous month, while gas volume also decreased by around 19.6%. Moreover, the recent sl","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/why-cross-timbers-royalty-trust-112419498.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CRT","BK4213"],"gpt_icon":0},{"id":"2529557053","title":"PennyMac Mortgage Investment Trust Reports First Quarter 2025 Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2529557053","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529557053?lang=en_us&edition=fundamental","pubTime":"2025-04-23 04:15","pubTimestamp":1745352900,"startTime":"0","endTime":"0","summary":"WESTLAKE VILLAGE, Calif., April 22, 2025----PennyMac Mortgage Investment Trust  today reported net loss attributable to common shareholders of $0.8 million, or $ per common share on a diluted basis for the first quarter of 2025, on net investment income of $44.5 million. PMT previously announced a cash dividend for the first quarter of 2025 of $0.40 per common share of beneficial interest, which was declared on March 6, 2025, and will be paid on April 25, 2025, to common shareholders of record as of April 11, 2025.Net loss attributable to common shareholders of $0.8 million; annualized return on average common equity of 0%1. \"PMT produced strong levels of income excluding market-driven value changes in the first quarter,\" said Chairman and CEO David Spector. \"This strong core performance was offset by net fair value declines due to interest rate volatility and credit spread widening. During the quarter, we opportunistically issued $173 million in unsecured senior notes, not only demons","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/pennymac-mortgage-investment-trust-reports-201500895.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4229","MBS","UPB","BK4195","BK4213","PFSI","CRT","REIT","BK4110","PMT","BK4139"],"gpt_icon":0},{"id":"2528274805","title":"FDA Approves WiSE® System, World's First and Only Leadless Left Ventricular Endocardial Pacing (LVEP) Device for CRT","url":"https://stock-news.laohu8.com/highlight/detail?id=2528274805","media":"PR Newswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528274805?lang=en_us&edition=fundamental","pubTime":"2025-04-17 21:27","pubTimestamp":1744896420,"startTime":"0","endTime":"0","summary":"Every once in a while, a breakthrough doesn't just advance medicine—it changes the conversation entirely.\"Recent years have brought significant advancements in leadless pacing for the right heart, but CRT patients were limited to traditional options—until now,\" said principal investigator Niraj Varma, MD, PhD, FRCP, Professor of Medicine at Cleveland Clinic. \"Now, the WiSE System brings a leadless solution to left ventricular pacing, eliminating the biggest limitation of conventional CRT: the lead. This is a game-changer for patients who were previously untreatable due to anatomy or lead failures.\". Patients with challenging anatomy where the LV lead could not be implanted. Patients with high procedural risk for LV lead placement. Backed by Data. Reimagining Delivery of CRT.The SOLVE-CRT trial has delivered promising results for heart failure patients. The WiSE System offers hope to those who have tried other therapies without success and were told no further options existed—until now.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance_au","url":"https://finance.yahoo.com/news/fda-approves-wise-system-worlds-132700453.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/fda-approves-wise-system-worlds-132700453.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["BK4213","EBR.AU","CRT","BK7007"],"gpt_icon":0},{"id":"2528716148","title":"Press Release: CROSS TIMBERS ROYALTY TRUST DECLARES APRIL CASH DISTRIBUTION","url":"https://stock-news.laohu8.com/highlight/detail?id=2528716148","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528716148?lang=en_us&edition=fundamental","pubTime":"2025-04-17 20:00","pubTimestamp":1744891200,"startTime":"0","endTime":"0","summary":"DALLAS, April 17, 2025 /PRNewswire/ -- Argent Trust Company, as Trustee of the Cross Timbers Royalty Trust  , today declared a cash distribution to the holders of its units of beneficial interest of $0.032110 per unit, payable on May 14, 2025, to unitholders of record on April 30, 2025. The following table shows underlying oil and gas sales and average prices attributable to the current month and prior month distributions.net profits income. Because of this, sales volumes may fluctuate from. In accordance with Section 3.08 of the Cross Timbers Royalty Trust Indenture, the Trustee has withheld $50,000 from this month's distribution to increase the amount of cash in the reserve account. The Trustee intends to continue to withhold $50,000 from distributable funds per month until the cash reserve has reached $1,500,000.For more information on the Trust, including the annual tax information, distribution amounts, and historical press releases, please visit our website at www.crt-crosstimber","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4211","BK4213","CRT","CASH"],"gpt_icon":0},{"id":"2527123886","title":"Which ASX company has just secured FDA approval?","url":"https://stock-news.laohu8.com/highlight/detail?id=2527123886","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527123886?lang=en_us&edition=fundamental","pubTime":"2025-04-15 05:24","pubTimestamp":1744665847,"startTime":"0","endTime":"0","summary":"EBR Systems Inc (ASX: EBR) shares were in the spotlight on Monday when the medical device company released some big news. The ASX company revealed that it has received FDA approval for its WiSE CRT Sy","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/04/15/which-asx-company-has-just-secured-fda-approval/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["EBR.AU","BK7007","CRT","BK4213"],"gpt_icon":0},{"id":"2527977273","title":"Australian Shares Rise Amidst Temporary Reprieve for Electronic Tariffs; EBR Systems Receives US FDA Approval for Heart Failure Treatment Device","url":"https://stock-news.laohu8.com/highlight/detail?id=2527977273","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527977273?lang=en_us&edition=fundamental","pubTime":"2025-04-14 14:59","pubTimestamp":1744613994,"startTime":"0","endTime":"0","summary":"Australian shares rose on Monday after US President Trump temporarily exempted China from a 125% tariff on popular electronics and introduced flat 10% tariffs on electronics around the globe.The S&P/A","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["NEU.AU","BK7508","BK7040","EBR","BK7082","CRT","XAO.AU","BK7007","XJO.AU","BK7501","EBR.AU","WOW.AU","COL.AU","BK7096","IE00B1B80R65.USD","BK4213","XKO.AU","BK4081","BK7511"],"gpt_icon":0},{"id":"2526840536","title":"U.S. Food and Drug Administration Approves Opdivo® (nivolumab) plus Yervoy® (ipilimumab) as a Treatment for Patients with Previously Untreated Microsatellite Instability-High or Mismatch Repair Deficient Unresectable or Metastatic Colorectal Cancer1","url":"https://stock-news.laohu8.com/highlight/detail?id=2526840536","media":"Business Wire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526840536?lang=en_us&edition=fundamental","pubTime":"2025-04-09 03:36","pubTimestamp":1744140960,"startTime":"0","endTime":"0","summary":"Based on the Phase 3 CheckMate-8HW trial, Opdivo plus Yervoy demonstrated reduction in the risk of disease progression or death by 79% vs. chemotherapy in the first-line setting and by 38% vs. Opdivo monotherapy across all lines of therapy 1. The approval was granted more than two months ahead of the Prescription Drug User Fee Act goal date. In the CheckMate-8HW trial, Opdivo plus Yervoy demonstrated a 38% reduction in the risk of disease progression or death vs. Opdivo monotherapy in immunotherapy-nave patients across all lines of therapy .1 Assessing the dual primary endpoint of PFS, the trial demonstrated that median PFS was not reached with Opdivo plus Yervoy  and was 39.3 months with Opdivo monotherapy .1 PFS rates at 12-, 24-, and 36-months were also numerically higher","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/u-food-drug-administration-approves-193600303.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4124","HCC","LU1093756325.SGD","BK4532","LU0985481810.HKD","LU1261432733.SGD","LU1989771016.USD","TEN","BK4144","LU1868837300.USD","LU1670711123.USD","IE00BFTCPJ56.SGD","IE0002141913.USD","LU1585245621.USD","OS","LU1670710661.SGD","CRT","BK4581","VOD","IE00B2B36J28.USD","BK4006","BK4534","LU1868836757.USD","LU1868837136.USD","CRC","LU0225284248.USD","LU2242646821.SGD","LU2242652126.USD","LU0868494617.USD","BK4132","HSCT","LU1670711040.USD","PFS","BMY","LU1670710588.SGD","LU0225771236.USD","LU1323610961.USD","IE0009355771.USD","LU1074936037.SGD","LU1032466523.USD","LU2133065610.SGD","LU1718418525.SGD","LU0237698245.USD","BK4211","LU0114720955.EUR","IE00BSNM7G36.USD","ORR","BK4195","LU1093756168.USD","LU0061475181.USD"],"gpt_icon":0},{"id":"2523491061","title":"IMFINZI® (durvalumab) approved in the US as first and only perioperative immunotherapy for patients with muscle-invasive bladder cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2523491061","media":"Business Wire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523491061?lang=en_us&edition=fundamental","pubTime":"2025-03-31 19:00","pubTimestamp":1743418800,"startTime":"0","endTime":"0","summary":"Based on NIAGARA Phase III trial results which showed a 32% reduction in the risk of recurrence and a 25% reduction in the risk of death vs. neoadjuvant chemotherapy alone. WILMINGTON, Del., March 31, 2025----AstraZeneca’s IMFINZI  in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by IMFINZI as adjuvant monotherapy after radical cystectomy  has been approved in the US for the treatment of adult patients with muscle-invasive bladder cancer .The approval was granted by the Food and Drug Administration  after securing Priority Review and was based on results from the NIAGARA Phase III trial which were presented during a Presidential Symposium at the 2024 European Society for Medical Oncology  Congress and simultaneously published in The New England Journal of Medicine.In the trial, patients were treated with four cycles of IMFI","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/imfinzi-durvalumab-approved-us-first-110000141.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1829250122.USD","LU0889565916.HKD","LU2456880835.USD","LU2417539215.USD","LU2462157665.USD","VOD","BK4144","BK4097","LU0109394709.USD","LU2236285917.USD","BK4023","AZN","BK4568","BK4132","BK4006","IE00BFMHRM44.USD","LU0320765992.SGD","BK4588","BK4213","BK4007","BK4124","HSCT","CRT","OS","BK4532","HCC","BK4543","BK4566","BK4585","NICE","TEN"],"gpt_icon":0},{"id":"2522257316","title":"Bristol Myers Squibb Receives Positive CHMP Opinion for the Subcutaneous Formulation of Opdivo® (nivolumab) Across Multiple Solid Tumor Indications","url":"https://stock-news.laohu8.com/highlight/detail?id=2522257316","media":"Business Wire","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522257316?lang=en_us&edition=fundamental","pubTime":"2025-03-28 20:00","pubTimestamp":1743163200,"startTime":"0","endTime":"0","summary":"Recommendation is based primarily on results from the Phase 3 CheckMate -67T trial which demonstrated noninferiority in the co-primary endpoints of Cavgd28 and Cminss and consistent efficacy in the secondary endpoint of overall response rate for the subcutaneous formulation of Opdivo vs. its intravenous formulation. A decision on the EU Opdivo extension of marketing authorization is expected by June 2, 2025. \"The positive CHMP opinion is an important step forward in the evolution of immuno-oncology and in the potential of subcutaneous nivolumab to help transform the lives of people living with cancer,\" said Dana Walker, M.D., M.S.C.E., Opdivo global program lead, Bristol Myers Squibb. \"We look forward to bringing the same high-quality care that transformed cancer treatment with an administration method that has the potential to improve the patient experience and efficiency of healthcare systems in Europe.\"","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/bristol-myers-squibb-receives-positive-120000105.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4528","BK4008","BK4532","LU1670711040.USD","IE00BFTCPJ56.SGD","BK4500","BK4559","LU1074936037.SGD","IE0009355771.USD","TEN","EC","CRT","LU1670710661.SGD","LU0061475181.USD","LU0321505439.SGD","BK4007","LU0096364046.USD","LU2133065610.SGD","LU0237698245.USD","LU1718418525.SGD","IE00BJJMRZ35.SGD","ALK","LU1323610961.USD","LU1093756168.USD","LU2242652126.USD","CHMP","LU0868494617.USD","LU0306807586.USD","LU1291159041.SGD","LU1670711123.USD","LU1868836914.USD","ORR","LU0882574055.USD","UK","HSCT","EEA","BK4534","LU0456855351.SGD","LU1261432733.SGD","VOD","IE0002141913.USD","LU1032466523.USD","BMY","LU1093756325.SGD","MYE","RCC","BK4156","LU1670710588.SGD","BK4585"],"gpt_icon":0},{"id":"2522837332","title":"New study results reinforce TAGRISSO® (osimertinib) as the backbone therapy for EGFR-mutated lung cancer across stages and settings","url":"https://stock-news.laohu8.com/highlight/detail?id=2522837332","media":"Business Wire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522837332?lang=en_us&edition=fundamental","pubTime":"2025-03-26 07:02","pubTimestamp":1742943720,"startTime":"0","endTime":"0","summary":"SAVANNAH and ORCHARD Phase II trials show the addition of savolitinib or datopotamab deruxtecan-dlnk to TAGRISSO upon disease progression demonstrates strong clinical activity. WILMINGTON, Del., March 25, 2025----New study results presented at the European Lung Cancer Congress  2025, March 26 to 29, demonstrate the role of AstraZeneca’s TAGRISSO , as monotherapy and as the backbone for novel combinations, across stages and settings of epidermal growth factor receptor-mutated  non-small cell lung cancer . Highlights include:. LAURA Phase III trial of TAGRISSO in unresectable, Stage III EGFRm NSCLC after chemoradiotherapy  .SAVANNAH Phase II trial of TAGRISSO plus savolitinib in advanced EGFRm NSCLC with high levels of MET overexpression and/or amplification following disease progression on 1st-line TAGRISSO (#2O).FLAURA2 Phase III trial of TAGRISSO plus chemotherapy as 1st-line treatment for advanced EGFRm NSCLC .Professor Virginia Harrison, EGFR Positive UK, said: \"For people undergoin","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/study-results-reinforce-tagrisso-osimertinib-230200995.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["OS","BK4124","BK4166","CRT","LU2462157665.USD","EMM","ORR","QD","LU2456880835.USD","BK4211","BK4097","BK4080","LU1829250122.USD","LU0109394709.USD","BK4007","BK4563","BK4195","BK4144","LU0889565916.HKD","LU2417539215.USD","BK4503","BK4213","LU2236285917.USD","ADC","BK4585","LU0320765992.SGD","BK4231","PFS","BK4588","BK4568","TEN","AZN"],"gpt_icon":1},{"id":"2522886659","title":"EBR Systems Advances Towards FDA Approval and Market Launch of WiSE CRT System","url":"https://stock-news.laohu8.com/highlight/detail?id=2522886659","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522886659?lang=en_us&edition=fundamental","pubTime":"2025-03-26 01:58","pubTimestamp":1742925508,"startTime":"0","endTime":"0","summary":"EBR Systems, Inc. Shs Chess Depository Interests Repr 1 Sh ( ($AU:EBR) ) has provided an announcement. EBR Systems, Inc. announced the submission o...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/ebr-systems-advances-towards-fda-approval-and-market-launch-of-wise-crt-system?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/ebr-systems-advances-towards-fda-approval-and-market-launch-of-wise-crt-system?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4081","CRT","EBR","BK4213","IE00B1B80R65.USD"],"gpt_icon":0},{"id":"2521117288","title":"Press Release: CROSS TIMBERS ROYALTY TRUST DECLARES MARCH CASH DISTRIBUTION","url":"https://stock-news.laohu8.com/highlight/detail?id=2521117288","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521117288?lang=en_us&edition=fundamental","pubTime":"2025-03-21 20:00","pubTimestamp":1742558400,"startTime":"0","endTime":"0","summary":"DALLAS, March 21, 2025 /PRNewswire/ -- Argent Trust Company, as Trustee of the Cross Timbers Royalty Trust  , today declared a cash distribution to the holders of its units of beneficial interest of $0.156725 per unit, payable on April 14, 2025, to unitholders of record on March 31, 2025. The following table shows underlying oil and gas sales and average prices attributable to the current month and prior month distributions.   Sales volumes are recorded in the month the Trust receives. the related net profits income. Because of this, sales. volumes may fluctuate from month to month based on the. XTO Energy has advised the Trustee that excess costs increased by $82,000 on properties underlying the Texas Working Interest net profits interests. However, these excess costs did not reduce net proceeds from the remaining conveyances. Underlying cumulative excess costs remaining on the Texas Working Interest net profits interests total $4,403,000, including accrued interest of $1,195,000.For ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRT","BK4213","BK4211","CASH"],"gpt_icon":0},{"id":"2520570285","title":"AZN's Imfinzi Gets EU Nod for Limited-Stage Small-Cell Lung Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2520570285","media":"Zacks","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520570285?lang=en_us&edition=fundamental","pubTime":"2025-03-17 23:10","pubTimestamp":1742224200,"startTime":"0","endTime":"0","summary":"AstraZeneca AZN recently announced that the European Commission has approved its blockbuster cancer drug Imfinzi  as monotherapy for treating limited-stage small cell lung cancer  in adult patients whose disease has not progressed following platinum-based chemoradiation therapy .The latest approval for Imfinzi in the European Union  was based on data from the phase III ADRIATIC study.Data from the phase III ADRIATIC study showed that treatment with Imfinzi reduced the risk of death by 27% as compared to placebo. Additionally, treatment with Imfinzi reduced the risk of disease progression or death by 24% versus placebo.The approval in the EU was expected as the Committee for Medicinal Products for Human Use recommended approval of Imfinzi as monotherapy for treating LS-SCLC in adult patients whose disease has not progressed following platinum-based CRT in February 2025.The FDA approved Imfinzi for a similar indication in December 2024.Hypoparathyroidism patients suffer from a deficiency","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/azns-imfinzi-gets-eu-nod-151000804.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4156","IE00B7SZLL34.SGD","BK4213","BMRN","SSI","BK4139","LU2236285917.USD","LU2417539215.USD","IE00B19Z3B42.SGD","BK4007","BK4588","CRT","LU0320765992.SGD","DVAX","LU2462157665.USD","BK4585","BK4568","LU0109394709.USD","LU2456880835.USD","BK4566","LU1829250122.USD","ARVN","IE00B19Z3581.USD","LU0889565916.HKD","IE0002270589.USD","AZN"],"gpt_icon":0},{"id":"2518287124","title":"SMART Trial two-year data continues to demonstrate superior valve performance for Evolut TAVR™ system in small annulus patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2518287124","media":"PR Newswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518287124?lang=en_us&edition=fundamental","pubTime":"2025-03-10 02:00","pubTimestamp":1741543200,"startTime":"0","endTime":"0","summary":"CRT 2025 Late Breaking Science features largest head-to-head randomized control TAVR trialto primarily enroll women using the two most widely used global TAVR devices. The SMART Trial is an international, prospective, multi-center, randomized (1:1) post-market trial comparing the safety and performance of Evolut self-expanding TAVR versus SAPIEN balloon-expandable TAVR in patients with symptomatic severe aortic stenosis  and small aortic annulus. The trial, the largest head to head randomized control trial to primarily enroll women, randomized and treated 716 patients, 87% of which were women, across more than 80 sites worldwide.2 Eligible patients had an aortic valve annulus area of ≤430 mmas measured by computed tomography, and suitable anatomy for tr","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/smart-trial-two-data-continues-180000059.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/smart-trial-two-data-continues-180000059.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0496365809.HKD","LU0211326755.USD","LU0211331839.USD","LU1291159041.SGD","LU0070302665.USD","LU0265550359.USD","LU0162691827.USD","LU2089283258.USD","IE00BQXX3C00.GBP","BK4082","LU1989771016.USD","IE000M9KFDE8.USD","IE00B3T34201.USD","LU0320765489.SGD","LU0265550946.USD","LU1571399168.USD","IE00BFXG1179.USD","CRT","LU1989764664.SGD","LU0211326839.USD","LU2468319806.SGD","IE00BQXX3D17.EUR","LU1116320737.USD","BK4566","LU0158827781.USD","LU0072461881.USD","LU2089284900.SGD","LU2271345857.HKD","MDT","LU0158827948.USD","BK4585","LU2028103732.USD","LU0976567544.SGD","IE00BQXX3F31.USD","LU1989764748.USD","BK4202","LU1116320901.HKD","LU0208291251.USD","LU2089984988.USD","BK4213","LU1983299246.USD","LU2111349929.HKD","LU2023251221.USD","AS","BK4533","BK4588"],"gpt_icon":0},{"id":"2517482934","title":"IMFINZI® (durvalumab)-based regimen demonstrated statistically significant and clinically meaningful improvement in event-free survival in resectable early-stage gastric and gastroesophageal junction cancers","url":"https://stock-news.laohu8.com/highlight/detail?id=2517482934","media":"Business Wire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517482934?lang=en_us&edition=fundamental","pubTime":"2025-03-07 20:00","pubTimestamp":1741348800,"startTime":"0","endTime":"0","summary":"MATTERHORN is first global, randomized Phase III trial to demonstrate superior event-free survival with an immunotherapy combination over standard of care in this setting. IMFINZI plus chemotherapy more than doubled pathologic complete response rate in previously reported analysis of this trial in 2023. WILMINGTON, Del., March 07, 2025----Positive high-level results from the MATTERHORN Phase III trial showed perioperative treatment with AstraZeneca’s IMFINZI  in combination with standard-of-care FLOT  chemotherapy demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint of event-free survival . Patients were treated with neoadjuvant IMFINZI in combination with chemotherapy before surgery, followed by adjuvant IMFINZI in combination with chemotherapy, then IMFINZI monotherapy. The trial evaluated this regimen versus perioperative chemotherapy alone for patients with resectable, early-stage and locally advanced  gastric and gastroesophageal j","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/imfinzi-durvalumab-based-regimen-demonstrated-120000536.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4588","HSCT","BK4585","BK4008","BK4144","LU1829250122.USD","LU0889565916.HKD","TEN","BK4500","BK4582","BK4006","LU2236285917.USD","BK4213","AZN","BK4532","LU0109394709.USD","BK4132","VOD","BK4124","BK4097","LU2417539215.USD","LU2456880835.USD","BK4156","FLOT","CRT","OS","BTC","HCC","BK4007","BK4568","LU2462157665.USD","ALK","LU0320765992.SGD"],"gpt_icon":0},{"id":"2517438854","title":"Bristol Myers Squibb Receives European Commission Approval for Opdivo® (nivolumab) plus Yervoy® (ipilimumab) for the First-Line Treatment of Adult Patients with Unresectable or Advanced Hepatocellular Carcinoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2517438854","media":"Business Wire","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517438854?lang=en_us&edition=fundamental","pubTime":"2025-03-07 19:59","pubTimestamp":1741348740,"startTime":"0","endTime":"0","summary":"Approval based on results of Phase 3 CheckMate -9DW clinical trial demonstrating a statistically significant and clinically meaningful improvement in overall survival with Opdivo plus Yervoy compared to investigator’s choice of lenvatinib or sorafenib. PRINCETON, N.J., March 07, 2025----Bristol Myers Squibb  today announced that the European Commission  has approved Opdivo  plus Yervoy  for the first-line treatment of adult patients with unresectable or advanced hepatocellular carcinoma .\"The European Commission’s approval for Opdivo plus Yervoy adds to the growing body of evidence demonstrating the value of dual immunotherapy and represents an important new treatment option that may extend survival for patients with hepatocellular carcinoma,\" said Dana Walker, M.D., M.S.C.E., vice president, Opdivo global program lead, Bristol Myers Squibb. \"This approval marks a critical milestone in our commitment to improving outcomes for patients with liver cancer. We look forward to bringing this","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/bristol-myers-squibb-receives-european-115900243.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00BFTCPJ56.SGD","BK4213","LU0225284248.USD","EC","LU0096364046.USD","LU1670710588.SGD","LU1261432733.SGD","LU2242646821.SGD","IE00BSNM7G36.USD","RCC","AEIS","LU2125154935.USD","HSCT","LU1032466523.USD","OS","TEN","IE00B7SZL793.SGD","ALK","LU0321505868.SGD","HCC","MYE","LU1868837300.USD","VOD","BMY","LU0306807586.USD","BK4132","LU0868494617.USD","LU1868836591.USD","ORR","CRC","BK4124","LU0306806265.USD","LU0321505439.SGD","LU0061475181.USD","LU0237698245.USD","BK4201","LU1291159041.SGD","LU1670711040.USD","LU0114720955.EUR","IE00B19Z4B17.USD","BK4157","LU1571399168.USD","LU1430594728.SGD","CRT","LU1868836914.USD","BK4097","BK4581","LU1868837136.USD","BK4532"],"gpt_icon":0},{"id":"2517157883","title":"Press Release: MCCOY GLOBAL ANNOUNCES FOURTH QUARTER AND YEAR END 2024 RESULTS AND INCREASE TO ITS QUARTERLY DIVIDEND","url":"https://stock-news.laohu8.com/highlight/detail?id=2517157883","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517157883?lang=en_us&edition=fundamental","pubTime":"2025-03-06 21:18","pubTimestamp":1741267080,"startTime":"0","endTime":"0","summary":"EDMONTON, AB, March 6, 2025 /CNW/ - McCoy Global Inc.   today announced its operational and financial results for the year and three months ended December 31, 2024.-- Revenue increased 28% to $25.2 million, compared to $19.7 million in Q4. 2023, driven by strong demand for recently commercialized smartProducts.smartProduct revenue5 accounted for $12.1 million, or 48%, of total. revenue, an increase of $3.9 million or 48% from Q4 2023.-- Net earnings of $4.3 million, a 59% increase from $2.7 million in 2023.-- Adjusted EBITDA1 increased to $6.5 million, or 26% of revenue, compared. to $4.0 million, or 20% of revenue, in 2023.-- Announced the increase of its quarterly cash dividend to $0.025 per. common share payable on April 15, 2025, to shareholders of record as of. -- Net earnings of $8.9 million, a 36% increase from $6.5 million in 2023.-- Adjusted EBITDA1 of $16.2 million, or 21% of revenue, compared to $13.1. integrated across these mergers. McCoy's FMS is a hydraulic rotary. to in","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FMS","BK4585","BK4196","YEAR","TM","BK4099","BK4588","CRT","BK4555","BK4604","BK4213","03160"],"gpt_icon":0},{"id":"2516666515","title":"Ekso Bionics Reports Fourth Quarter and Full-Year 2024 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2516666515","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516666515?lang=en_us&edition=fundamental","pubTime":"2025-03-04 05:05","pubTimestamp":1741035900,"startTime":"0","endTime":"0","summary":"SAN RAFAEL, Calif., March 03, 2025  -- Ekso Bionics Holdings, Inc.  , an industry leader in exoskeleton technology for medical and industrial use, today reported financial results for the three and twelve months ended December 31, 2024.Q4-2024 gross margin increased 400 basis points year-over-year to 53%. “We are pleased to close out 2024 with record fourth quarter revenue, improved gross margin and growing interest in our unrivalled portfolio of Enterprise Health and Personal Health devices,” said Scott Davis, the Company’s Chief Executive Officer. “Looking ahead, our focus will be on aggressively executing two key pillars of our growth strategy:  broadening patient access to Ekso Indego Personal and building upon our growing CMS claim pipeline for the device; and  further bolstering demand for our legacy EksoNR device. We look forward to updating investors as we progress.”Research and development expenses for the three months ended December 31, 2024 were $845,000, compared to $1.3 mi","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/ekso-bionics-reports-fourth-quarter-210500536.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["EKSO","BK4082","CRT","BK4213"],"gpt_icon":0},{"id":"2514381094","title":"Press Release: Robotic Telesurgery Data from Collaboration with Corewell Health(TM) Accepted for Presentation at the Cardiovascular Research Technologies Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2514381094","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514381094?lang=en_us&edition=fundamental","pubTime":"2025-02-25 21:30","pubTimestamp":1740490200,"startTime":"0","endTime":"0","summary":"Robotic Telesurgery Data from Collaboration with Corewell Health Accepted for Presentation at the Cardiovascular Research Technologies Annual Meeting. Research Collaboration demonstrates the feasibility of using the LIBERTY Endovascular Robotic System between separate and remote facilities in a coronary simulation model. BRAINTREE, Mass., Feb. 25, 2025  -- Microbot Medical Inc. , developer of the innovative LIBERTY Endovascular Robotic System, today announced its collaboration with Corewell Health has reached another meaningful milestone. Under a collaboration agreement, Microbot Medical and Corewell Health are working together to advance robotic telesurgery for endovascular applications. Led by Ryan Madder, M.D., Section Chief of Interventional Cardiology and Director of the Cardiac Cath Lab at Corewell Health in Grand Rapids, Michigan, the project assesses the feasibility of using LIBERTY to perform simulated cardiovascular interventional procedures across two sites within the Corewe","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4213","CRT","03160","BK4585","CSII","BK4022","MBOT","BK4082","BK4099","BK4604","BK4555","TM","BK4588","R","BK4232"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":46,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CRT\",params:#limit:5,,,undefined,":[{"date":"2025-04-30","symbol":"CRT","amount":0.03211,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-04-30","defaultRemindTime":1746019800000,"name":"CRT信托","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-05-14","payableDate":"2025-04-30","currency":"USD","dateTimestamp":1745985600000,"payDate":"2025-05-14"},{"date":"2025-03-31","symbol":"CRT","amount":0.156725,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-03-31","defaultRemindTime":1743427800000,"name":"CRT信托","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-04-14","payableDate":"2025-03-31","currency":"USD","dateTimestamp":1743393600000,"payDate":"2025-04-14"},{"market":"US","date":"2025-03-27","symbol":"CRT","fiscalQuarterEnding":"2024/12","expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1743048000000,"reportTimeType":"post","actualEps":0.22},{"date":"2025-02-28","symbol":"CRT","amount":0.045553,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-02-28","defaultRemindTime":1740753000000,"name":"CRT信托","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-03-14","payableDate":"2025-02-28","currency":"USD","dateTimestamp":1740718800000,"payDate":"2025-03-14"},{"date":"2025-01-31","symbol":"CRT","amount":0.09505,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-01-31","defaultRemindTime":1738333800000,"name":"CRT信托","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-02-14","payableDate":"2025-01-31","currency":"USD","dateTimestamp":1738299600000,"payDate":"2025-02-14"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CRT\",market:\"US\",,,undefined,":[{"executeDate":"2015-04-28","recordDate":"2015-04-30","paymentDate":"2015-05-14","value":0.156955,"currency":"USD"},{"executeDate":"2015-05-27","recordDate":"2015-05-29","paymentDate":"2015-06-12","value":0.05237,"currency":"USD"},{"executeDate":"2015-06-26","recordDate":"2015-06-30","paymentDate":"2015-07-14","value":0.080113,"currency":"USD"},{"executeDate":"2015-07-29","recordDate":"2015-07-31","paymentDate":"2015-08-14","value":0.099748,"currency":"USD"},{"executeDate":"2015-08-27","recordDate":"2015-08-31","paymentDate":"2015-09-15","value":0.099341,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"CRT\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/CRT\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"CRT","date":"2025-04-25","current":10.736519,"percent":0.575264,"low":5.926909,"twenty":8.165725,"median":10.052751,"eighty":14.103137,"high":20.651413,"avg":10.997247,"sd":3.377265,"marketCap":60960000},"quantilePoints":[{"date":"2020-05-01","current":6.711125,"twenty":6.656169,"median":9.075387,"eighty":12.467109,"marketCap":35280600},{"date":"2020-05-08","current":7.133303,"twenty":6.656169,"median":9.067856,"eighty":12.467109,"marketCap":37500000},{"date":"2020-05-15","current":6.242811,"twenty":6.592125,"median":9.067856,"eighty":12.467109,"marketCap":37350000},{"date":"2020-05-22","current":7.330915,"twenty":6.571342,"median":9.067856,"eighty":12.467109,"marketCap":43860000},{"date":"2020-05-29","current":7.2206,"twenty":6.571342,"median":9.067856,"eighty":12.467109,"marketCap":43200000},{"date":"2020-06-05","current":7.782203,"twenty":6.571342,"median":9.067856,"eighty":12.467109,"marketCap":46560000},{"date":"2020-06-12","current":7.561573,"twenty":6.571342,"median":9.067856,"eighty":12.467109,"marketCap":45240000},{"date":"2020-06-19","current":7.270743,"twenty":6.621907,"median":9.067856,"eighty":12.467109,"marketCap":43500000},{"date":"2020-06-26","current":7.361001,"twenty":6.672159,"median":9.067856,"eighty":12.467109,"marketCap":44040000},{"date":"2020-07-02","current":7.1504,"twenty":6.699118,"median":9.067856,"eighty":12.467109,"marketCap":42780000},{"date":"2020-07-10","current":6.689084,"twenty":6.710103,"median":9.067856,"eighty":12.467109,"marketCap":40020000},{"date":"2020-07-17","current":6.187653,"twenty":6.710103,"median":9.067856,"eighty":12.467109,"marketCap":37020000},{"date":"2020-07-24","current":6.614672,"twenty":6.710103,"median":9.067856,"eighty":12.467109,"marketCap":39574800},{"date":"2020-07-31","current":6.232782,"twenty":6.710103,"median":9.067856,"eighty":12.467109,"marketCap":37290000},{"date":"2020-08-07","current":6.368168,"twenty":6.710103,"median":9.067856,"eighty":12.467109,"marketCap":38100000},{"date":"2020-08-14","current":6.860703,"twenty":6.757678,"median":9.067856,"eighty":12.467109,"marketCap":36855600},{"date":"2020-08-21","current":6.768447,"twenty":6.771178,"median":9.067856,"eighty":12.467109,"marketCap":36360000},{"date":"2020-08-28","current":7.159363,"twenty":6.810956,"median":9.067856,"eighty":12.467109,"marketCap":38460000},{"date":"2020-09-04","current":6.835461,"twenty":6.821019,"median":9.067856,"eighty":12.467109,"marketCap":36720000},{"date":"2020-09-11","current":6.857799,"twenty":6.835587,"median":9.067856,"eighty":12.467109,"marketCap":36840000},{"date":"2020-09-18","current":6.768223,"twenty":6.858116,"median":9.067856,"eighty":12.467109,"marketCap":36358800},{"date":"2020-09-25","current":6.48922,"twenty":6.858116,"median":9.067856,"eighty":12.467109,"marketCap":34860000},{"date":"2020-10-02","current":6.098303,"twenty":6.858116,"median":9.067856,"eighty":12.467109,"marketCap":32760000},{"date":"2020-10-09","current":6.243278,"twenty":6.838644,"median":9.067856,"eighty":12.467109,"marketCap":33538800},{"date":"2020-10-16","current":6.511558,"twenty":6.835587,"median":9.067856,"eighty":12.467109,"marketCap":34980000},{"date":"2020-10-23","current":7.349237,"twenty":6.858116,"median":9.067856,"eighty":12.467109,"marketCap":39480000},{"date":"2020-10-30","current":8.209254,"twenty":6.878433,"median":9.067856,"eighty":12.467109,"marketCap":44100000},{"date":"2020-11-06","current":9.244814,"twenty":6.902826,"median":9.074987,"eighty":12.467109,"marketCap":44940000},{"date":"2020-11-13","current":10.330987,"twenty":6.924813,"median":9.120614,"eighty":12.467109,"marketCap":50220000},{"date":"2020-11-20","current":9.911329,"twenty":6.945184,"median":9.150702,"eighty":12.467109,"marketCap":48180000},{"date":"2020-11-27","current":10.232244,"twenty":6.96358,"median":9.162951,"eighty":12.467109,"marketCap":49740000},{"date":"2020-12-04","current":9.627443,"twenty":6.990733,"median":9.188359,"eighty":12.467109,"marketCap":46800000},{"date":"2020-12-11","current":9.849614,"twenty":7.015283,"median":9.202046,"eighty":12.467109,"marketCap":47880000},{"date":"2020-12-18","current":10.368015,"twenty":7.04534,"median":9.226016,"eighty":12.467109,"marketCap":50400000},{"date":"2020-12-24","current":10.491444,"twenty":7.072885,"median":9.248611,"eighty":12.467109,"marketCap":51000000},{"date":"2020-12-31","current":10.170529,"twenty":7.087866,"median":9.262892,"eighty":12.467109,"marketCap":49440000},{"date":"2021-01-08","current":10.392701,"twenty":7.129213,"median":9.27535,"eighty":12.467109,"marketCap":50520000},{"date":"2021-01-15","current":10.195215,"twenty":7.152193,"median":9.286268,"eighty":12.467109,"marketCap":49560000},{"date":"2021-01-22","current":10.244586,"twenty":7.172744,"median":9.299784,"eighty":12.467109,"marketCap":49800000},{"date":"2021-01-29","current":9.504014,"twenty":7.214589,"median":9.338988,"eighty":12.467109,"marketCap":46200000},{"date":"2021-02-05","current":10.021057,"twenty":7.229231,"median":9.355899,"eighty":12.467109,"marketCap":48713400},{"date":"2021-02-12","current":10.151027,"twenty":7.250221,"median":9.371894,"eighty":12.467109,"marketCap":49345200},{"date":"2021-02-19","current":11.096245,"twenty":7.270743,"median":9.409785,"eighty":12.467109,"marketCap":53940000},{"date":"2021-02-26","current":10.923445,"twenty":7.292398,"median":9.441362,"eighty":12.467109,"marketCap":53100000},{"date":"2021-03-05","current":11.355445,"twenty":7.34712,"median":9.497564,"eighty":12.468828,"marketCap":55200000},{"date":"2021-03-12","current":12.453961,"twenty":7.361001,"median":9.566299,"eighty":12.482371,"marketCap":60540000},{"date":"2021-03-19","current":11.269045,"twenty":7.408933,"median":9.622888,"eighty":12.482371,"marketCap":54780000},{"date":"2021-03-26","current":10.68893,"twenty":7.423035,"median":9.639786,"eighty":12.479662,"marketCap":51960000},{"date":"2021-04-01","current":10.60253,"twenty":7.49369,"median":9.656657,"eighty":12.479662,"marketCap":51540000},{"date":"2021-04-09","current":11.071559,"twenty":7.531804,"median":9.703447,"eighty":12.482371,"marketCap":53820000},{"date":"2021-04-16","current":11.140889,"twenty":7.556966,"median":9.750871,"eighty":12.482371,"marketCap":52080000},{"date":"2021-04-23","current":12.180534,"twenty":7.571602,"median":9.766899,"eighty":12.482371,"marketCap":56940000},{"date":"2021-04-30","current":12.616928,"twenty":7.615202,"median":9.806414,"eighty":12.494608,"marketCap":58980000},{"date":"2021-05-07","current":13.078992,"twenty":7.682222,"median":9.841907,"eighty":12.503201,"marketCap":61140000},{"date":"2021-05-14","current":15.610404,"twenty":7.717157,"median":9.883983,"eighty":12.526935,"marketCap":60960000},{"date":"2021-05-21","current":15.164831,"twenty":7.782203,"median":9.913169,"eighty":12.536097,"marketCap":59220000},{"date":"2021-05-28","current":14.965092,"twenty":7.824611,"median":9.944313,"eighty":12.546167,"marketCap":58440000},{"date":"2021-06-04","current":15.287748,"twenty":7.872851,"median":9.971976,"eighty":12.563354,"marketCap":59700000},{"date":"2021-06-11","current":15.441393,"twenty":7.880546,"median":9.985386,"eighty":12.571947,"marketCap":60300000},{"date":"2021-06-18","current":15.56431,"twenty":7.893169,"median":10.010072,"eighty":12.587481,"marketCap":60780000},{"date":"2021-06-25","current":18.667953,"twenty":7.939412,"median":10.034758,"eighty":12.598778,"marketCap":72900000},{"date":"2021-07-02","current":17.223684,"twenty":7.951639,"median":10.096472,"eighty":12.615118,"marketCap":67260000},{"date":"2021-07-09","current":17.607798,"twenty":7.960357,"median":10.108815,"eighty":12.630808,"marketCap":68760000},{"date":"2021-07-16","current":17.377329,"twenty":7.960357,"median":10.145843,"eighty":12.639613,"marketCap":67860000},{"date":"2021-07-23","current":19.174984,"twenty":7.98167,"median":10.167447,"eighty":12.659667,"marketCap":74880000},{"date":"2021-07-30","current":18.775505,"twenty":7.995539,"median":10.182872,"eighty":12.68366,"marketCap":73320000},{"date":"2021-08-06","current":17.822902,"twenty":8.009454,"median":10.199165,"eighty":12.711966,"marketCap":69600000},{"date":"2021-08-13","current":16.150292,"twenty":8.009454,"median":10.234666,"eighty":12.756936,"marketCap":72120000},{"date":"2021-08-20","current":15.263504,"twenty":8.009454,"median":10.256929,"eighty":12.783365,"marketCap":68160000},{"date":"2021-08-27","current":16.365271,"twenty":8.009454,"median":10.287786,"eighty":12.818164,"marketCap":73080000},{"date":"2021-09-03","current":16.926634,"twenty":8.009454,"median":10.331402,"eighty":12.833711,"marketCap":75586800},{"date":"2021-09-10","current":16.123419,"twenty":8.009454,"median":10.374187,"eighty":12.854872,"marketCap":72000000},{"date":"2021-09-17","current":17.440165,"twenty":8.009454,"median":10.417731,"eighty":12.882425,"marketCap":77880000},{"date":"2021-09-24","current":19.240614,"twenty":8.009454,"median":10.504955,"eighty":12.917553,"marketCap":85920000},{"date":"2021-10-01","current":19.106252,"twenty":8.009454,"median":10.583661,"eighty":12.944662,"marketCap":85320000},{"date":"2021-10-08","current":20.651413,"twenty":8.009454,"median":10.62548,"eighty":12.95853,"marketCap":92220000},{"date":"2021-10-15","current":20.328945,"twenty":8.009454,"median":10.662788,"eighty":12.983815,"marketCap":90780000},{"date":"2021-10-22","current":18.461315,"twenty":8.009454,"median":10.691788,"eighty":13.049275,"marketCap":82440000},{"date":"2021-10-29","current":18.434443,"twenty":8.009707,"median":10.732305,"eighty":13.08048,"marketCap":82320000},{"date":"2021-11-05","current":19.227178,"twenty":8.009707,"median":10.742312,"eighty":13.162363,"marketCap":85860000},{"date":"2021-11-12","current":13.602537,"twenty":8.009707,"median":10.792834,"eighty":13.230652,"marketCap":83700000},{"date":"2021-11-19","current":11.067297,"twenty":8.009707,"median":10.807619,"eighty":13.238255,"marketCap":68100000},{"date":"2021-11-26","current":11.896125,"twenty":8.009707,"median":10.807619,"eighty":13.238255,"marketCap":73200000},{"date":"2021-12-03","current":9.750922,"twenty":8.009707,"median":10.807619,"eighty":13.238255,"marketCap":60000000},{"date":"2021-12-10","current":10.696762,"twenty":8.009707,"median":10.739836,"eighty":13.238255,"marketCap":65820000},{"date":"2021-12-17","current":10.277472,"twenty":8.009707,"median":10.717242,"eighty":13.238255,"marketCap":63240000},{"date":"2021-12-23","current":11.31107,"twenty":8.009707,"median":10.717242,"eighty":13.238255,"marketCap":69600000},{"date":"2021-12-31","current":11.174557,"twenty":8.009707,"median":10.717242,"eighty":13.238255,"marketCap":68760000},{"date":"2022-01-07","current":11.769363,"twenty":8.009961,"median":10.721601,"eighty":13.234818,"marketCap":72420000},{"date":"2022-01-14","current":13.066236,"twenty":8.009961,"median":10.721601,"eighty":13.234818,"marketCap":80400000},{"date":"2022-01-21","current":13.10524,"twenty":8.009961,"median":10.721601,"eighty":13.258494,"marketCap":80640000},{"date":"2022-01-28","current":13.446522,"twenty":8.009961,"median":10.721601,"eighty":13.281823,"marketCap":82740000},{"date":"2022-02-04","current":14.528874,"twenty":8.009961,"median":10.721601,"eighty":13.31505,"marketCap":89400000},{"date":"2022-02-11","current":14.558127,"twenty":8.009961,"median":10.736902,"eighty":13.338305,"marketCap":89580000},{"date":"2022-02-18","current":14.236347,"twenty":8.009961,"median":10.749664,"eighty":13.393471,"marketCap":87600000},{"date":"2022-02-25","current":14.894534,"twenty":8.009961,"median":10.830284,"eighty":13.417826,"marketCap":91650000},{"date":"2022-03-04","current":15.484465,"twenty":8.009961,"median":10.946951,"eighty":13.471216,"marketCap":95280000},{"date":"2022-03-11","current":15.845249,"twenty":8.009961,"median":10.986766,"eighty":13.51972,"marketCap":97500000},{"date":"2022-03-18","current":14.314354,"twenty":8.009961,"median":11.077731,"eighty":13.580741,"marketCap":88080000},{"date":"2022-03-25","current":13.573284,"twenty":8.009961,"median":11.122435,"eighty":13.603533,"marketCap":83520000},{"date":"2022-04-01","current":11.814241,"twenty":8.009961,"median":11.145616,"eighty":13.603533,"marketCap":78840000},{"date":"2022-04-08","current":12.092964,"twenty":8.009961,"median":11.211742,"eighty":13.603533,"marketCap":80700000},{"date":"2022-04-14","current":12.362695,"twenty":8.009961,"median":11.256702,"eighty":13.603533,"marketCap":82500000},{"date":"2022-04-22","current":13.369693,"twenty":8.009961,"median":11.319498,"eighty":13.614314,"marketCap":89220000},{"date":"2022-04-29","current":13.468595,"twenty":8.009961,"median":11.352759,"eighty":13.641654,"marketCap":89880000},{"date":"2022-05-06","current":14.250816,"twenty":8.009961,"median":11.413684,"eighty":13.675545,"marketCap":95100000},{"date":"2022-05-13","current":12.993784,"twenty":8.009961,"median":11.413684,"eighty":13.70999,"marketCap":95100000},{"date":"2022-05-20","current":15.010485,"twenty":8.009961,"median":11.413684,"eighty":13.753017,"marketCap":109860000},{"date":"2022-05-27","current":15.641729,"twenty":8.009961,"median":11.413684,"eighty":13.801264,"marketCap":114480000},{"date":"2022-06-03","current":14.567795,"twenty":8.009961,"median":11.413684,"eighty":13.826646,"marketCap":106620000},{"date":"2022-06-10","current":15.79749,"twenty":8.009961,"median":11.413684,"eighty":13.873668,"marketCap":115620000},{"date":"2022-06-17","current":14.297262,"twenty":8.009961,"median":11.413684,"eighty":13.874468,"marketCap":104640000},{"date":"2022-06-24","current":14.059521,"twenty":8.009707,"median":11.410988,"eighty":13.897974,"marketCap":102900000},{"date":"2022-07-01","current":12.387134,"twenty":8.009707,"median":11.410988,"eighty":13.933076,"marketCap":90660000},{"date":"2022-07-08","current":11.928048,"twenty":8.009707,"median":11.398828,"eighty":13.933076,"marketCap":87300000},{"date":"2022-07-15","current":13.059368,"twenty":8.009707,"median":11.398828,"eighty":13.933076,"marketCap":95580000},{"date":"2022-07-22","current":13.993937,"twenty":8.009707,"median":11.398828,"eighty":13.954875,"marketCap":102420000},{"date":"2022-07-29","current":15.010485,"twenty":8.009707,"median":11.398828,"eighty":13.979654,"marketCap":109860000},{"date":"2022-08-05","current":14.567795,"twenty":8.009707,"median":11.398828,"eighty":14.001242,"marketCap":106620000},{"date":"2022-08-12","current":12.549381,"twenty":8.009707,"median":11.398828,"eighty":14.029636,"marketCap":115560000},{"date":"2022-08-19","current":12.823044,"twenty":8.009707,"median":11.398828,"eighty":14.029636,"marketCap":118080000},{"date":"2022-08-26","current":14.72565,"twenty":8.009707,"median":11.398828,"eighty":14.055815,"marketCap":135600000},{"date":"2022-09-02","current":13.298695,"twenty":8.009707,"median":11.398828,"eighty":14.084883,"marketCap":122460000},{"date":"2022-09-09","current":14.09362,"twenty":8.009707,"median":11.398828,"eighty":14.09169,"marketCap":129780000},{"date":"2022-09-16","current":14.393346,"twenty":8.009707,"median":11.398828,"eighty":14.141203,"marketCap":132540000},{"date":"2022-09-23","current":11.500342,"twenty":8.009707,"median":11.398828,"eighty":14.141203,"marketCap":105900000},{"date":"2022-09-30","current":12.575445,"twenty":8.009707,"median":11.355445,"eighty":14.141203,"marketCap":115800000},{"date":"2022-10-07","current":15.051439,"twenty":8.009707,"median":11.355445,"eighty":14.215272,"marketCap":138600000},{"date":"2022-10-14","current":13.865568,"twenty":8.009707,"median":11.355445,"eighty":14.215272,"marketCap":127680000},{"date":"2022-10-21","current":14.764745,"twenty":8.009707,"median":11.355445,"eighty":14.245895,"marketCap":135960000},{"date":"2022-10-28","current":15.038407,"twenty":8.009707,"median":11.355445,"eighty":14.280469,"marketCap":138480000},{"date":"2022-11-04","current":13.318243,"twenty":8.009707,"median":11.355445,"eighty":14.280469,"marketCap":122640000},{"date":"2022-11-11","current":14.080588,"twenty":8.009707,"median":11.355445,"eighty":14.280469,"marketCap":129660000},{"date":"2022-11-18","current":11.855702,"twenty":8.009707,"median":11.355445,"eighty":14.280469,"marketCap":126180000},{"date":"2022-11-25","current":12.566029,"twenty":8.009707,"median":11.355445,"eighty":14.280469,"marketCap":133740000},{"date":"2022-12-02","current":14.048697,"twenty":8.009707,"median":11.355445,"eighty":14.280469,"marketCap":149520000},{"date":"2022-12-09","current":12.340529,"twenty":8.009707,"median":11.355445,"eighty":14.280469,"marketCap":131340000},{"date":"2022-12-16","current":12.374354,"twenty":8.009707,"median":11.355445,"eighty":14.280469,"marketCap":131700000},{"date":"2022-12-23","current":14.116347,"twenty":8.009707,"median":11.355445,"eighty":14.280469,"marketCap":150240000},{"date":"2022-12-30","current":14.341848,"twenty":8.009707,"median":11.355445,"eighty":14.300488,"marketCap":152640000},{"date":"2023-01-06","current":13.394745,"twenty":8.009707,"median":11.355445,"eighty":14.298116,"marketCap":142560000},{"date":"2023-01-13","current":13.930309,"twenty":8.009707,"median":11.355445,"eighty":14.255346,"marketCap":148260000},{"date":"2023-01-20","current":14.392586,"twenty":8.009707,"median":11.355445,"eighty":14.237759,"marketCap":153180000},{"date":"2023-01-27","current":15.142376,"twenty":8.009707,"median":11.355445,"eighty":14.237759,"marketCap":161160000},{"date":"2023-02-03","current":14.747749,"twenty":8.009707,"median":11.355445,"eighty":14.255346,"marketCap":156960000},{"date":"2023-02-10","current":15.531364,"twenty":8.009707,"median":11.355445,"eighty":14.299207,"marketCap":165300000},{"date":"2023-02-17","current":15.046538,"twenty":8.009707,"median":11.355445,"eighty":14.346809,"marketCap":160140000},{"date":"2023-02-24","current":11.461076,"twenty":8.009707,"median":11.355445,"eighty":14.307017,"marketCap":121980000},{"date":"2023-03-03","current":10.637998,"twenty":8.009707,"median":11.330572,"eighty":14.275418,"marketCap":113220000},{"date":"2023-03-10","current":9.08768,"twenty":8.009707,"median":11.297163,"eighty":14.263524,"marketCap":96720000},{"date":"2023-03-17","current":7.616288,"twenty":8.006501,"median":11.244359,"eighty":14.219343,"marketCap":81060000},{"date":"2023-03-24","current":9.335731,"twenty":7.99797,"median":11.166559,"eighty":14.118602,"marketCap":99360000},{"date":"2023-03-31","current":9.554436,"twenty":8.000401,"median":11.139946,"eighty":14.077625,"marketCap":112200000},{"date":"2023-04-06","current":9.83034,"twenty":8.000401,"median":11.112498,"eighty":14.050862,"marketCap":115440000},{"date":"2023-04-14","current":10.004057,"twenty":7.995539,"median":11.084934,"eighty":14.055191,"marketCap":117480000},{"date":"2023-04-21","current":10.893079,"twenty":7.995539,"median":10.989993,"eighty":14.055191,"marketCap":127920000},{"date":"2023-04-28","current":10.673378,"twenty":7.995539,"median":10.986766,"eighty":14.055191,"marketCap":125340000},{"date":"2023-05-05","current":10.305507,"twenty":7.993108,"median":10.958248,"eighty":14.057356,"marketCap":121020000},{"date":"2023-05-12","current":10.770455,"twenty":7.993108,"median":10.852808,"eighty":14.057356,"marketCap":126480000},{"date":"2023-05-19","current":8.852709,"twenty":7.993108,"median":10.807619,"eighty":14.057356,"marketCap":121260000},{"date":"2023-05-26","current":9.299506,"twenty":7.993108,"median":10.746539,"eighty":14.057356,"marketCap":127380000},{"date":"2023-06-02","current":9.10677,"twenty":7.993108,"median":10.725959,"eighty":14.057356,"marketCap":124740000},{"date":"2023-06-09","current":10.469062,"twenty":7.993108,"median":10.694647,"eighty":14.057356,"marketCap":143400000},{"date":"2023-06-16","current":11.1743,"twenty":7.993108,"median":10.679585,"eighty":14.057356,"marketCap":153060000},{"date":"2023-06-23","current":9.553567,"twenty":7.990677,"median":10.672528,"eighty":14.059521,"marketCap":130860000},{"date":"2023-06-30","current":9.908376,"twenty":7.990677,"median":10.622285,"eighty":14.062431,"marketCap":135720000},{"date":"2023-07-07","current":9.281984,"twenty":7.990677,"median":10.565501,"eighty":14.062431,"marketCap":127140000},{"date":"2023-07-14","current":8.440955,"twenty":7.990677,"median":10.513893,"eighty":14.062431,"marketCap":115620000},{"date":"2023-07-21","current":8.546084,"twenty":7.990677,"median":10.454415,"eighty":14.062431,"marketCap":117060000},{"date":"2023-07-28","current":9.067347,"twenty":7.990677,"median":10.39339,"eighty":14.062431,"marketCap":124200000},{"date":"2023-08-04","current":9.067347,"twenty":7.990677,"median":10.373035,"eighty":14.062431,"marketCap":124200000},{"date":"2023-08-11","current":8.953457,"twenty":7.990677,"median":10.355733,"eighty":14.062431,"marketCap":122640000},{"date":"2023-08-18","current":9.683499,"twenty":7.990677,"median":10.316476,"eighty":14.062431,"marketCap":127620000},{"date":"2023-08-25","current":9.159944,"twenty":7.990677,"median":10.269272,"eighty":14.062431,"marketCap":120720000},{"date":"2023-09-01","current":9.455867,"twenty":7.990677,"median":10.241637,"eighty":14.065342,"marketCap":124620000},{"date":"2023-09-08","current":9.264655,"twenty":7.990677,"median":10.22431,"eighty":14.065342,"marketCap":122100000},{"date":"2023-09-15","current":10.289003,"twenty":7.990677,"median":10.191603,"eighty":14.065342,"marketCap":135600000},{"date":"2023-09-22","current":8.909548,"twenty":7.990677,"median":10.170529,"eighty":14.065342,"marketCap":117420000},{"date":"2023-09-29","current":9.146286,"twenty":7.990677,"median":10.152227,"eighty":14.065342,"marketCap":120540000},{"date":"2023-10-06","current":8.39965,"twenty":7.990677,"median":10.143374,"eighty":14.065342,"marketCap":110700000},{"date":"2023-10-13","current":8.581757,"twenty":7.990677,"median":10.10424,"eighty":14.065342,"marketCap":113100000},{"date":"2023-10-20","current":8.404203,"twenty":7.990677,"median":10.055124,"eighty":14.065342,"marketCap":110760000},{"date":"2023-10-27","current":8.135596,"twenty":7.990677,"median":10.034758,"eighty":14.074073,"marketCap":107220000},{"date":"2023-11-03","current":8.422414,"twenty":7.990677,"median":10.010072,"eighty":14.074073,"marketCap":111000000},{"date":"2023-11-10","current":8.24486,"twenty":7.990677,"median":9.985386,"eighty":14.074073,"marketCap":108660000},{"date":"2023-11-17","current":9.372752,"twenty":7.990677,"median":9.962963,"eighty":14.074073,"marketCap":111480000},{"date":"2023-11-24","current":10.184923,"twenty":7.990677,"median":9.948357,"eighty":14.074073,"marketCap":121140000},{"date":"2023-12-01","current":9.468598,"twenty":7.990677,"median":9.932561,"eighty":14.074073,"marketCap":112620000},{"date":"2023-12-08","current":9.519044,"twenty":7.990677,"median":9.911329,"eighty":14.071163,"marketCap":113220000},{"date":"2023-12-15","current":9.100347,"twenty":7.990677,"median":9.884038,"eighty":14.071163,"marketCap":108240000},{"date":"2023-12-22","current":9.266817,"twenty":7.990677,"median":9.870083,"eighty":14.071163,"marketCap":110220000},{"date":"2023-12-29","current":8.974234,"twenty":7.990677,"median":9.871214,"eighty":14.074073,"marketCap":106740000},{"date":"2024-01-05","current":8.933877,"twenty":7.990091,"median":9.876268,"eighty":14.074635,"marketCap":106260000},{"date":"2024-01-12","current":8.827942,"twenty":7.990091,"median":9.876268,"eighty":14.074635,"marketCap":105000000},{"date":"2024-01-19","current":8.550492,"twenty":7.989505,"median":9.868953,"eighty":14.075197,"marketCap":101700000},{"date":"2024-01-26","current":9.12557,"twenty":7.990091,"median":9.862382,"eighty":14.074635,"marketCap":108540000},{"date":"2024-02-02","current":9.01459,"twenty":7.990091,"median":9.862382,"eighty":14.074635,"marketCap":107220000},{"date":"2024-02-09","current":8.653098,"twenty":7.990091,"median":9.862382,"eighty":14.074635,"marketCap":102920400},{"date":"2024-02-16","current":8.807764,"twenty":7.990091,"median":9.862382,"eighty":14.074635,"marketCap":104760000},{"date":"2024-02-23","current":8.752274,"twenty":7.990091,"median":9.862382,"eighty":14.074635,"marketCap":104100000},{"date":"2024-03-01","current":8.621116,"twenty":7.990677,"median":9.855812,"eighty":14.074073,"marketCap":102540000},{"date":"2024-03-08","current":8.460195,"twenty":7.990677,"median":9.855812,"eighty":14.074073,"marketCap":100626000},{"date":"2024-03-15","current":8.716962,"twenty":7.990677,"median":9.855812,"eighty":14.074073,"marketCap":103680000},{"date":"2024-03-22","current":6.366207,"twenty":7.967059,"median":9.855812,"eighty":14.074073,"marketCap":75720000},{"date":"2024-03-28","current":6.608345,"twenty":7.950304,"median":9.855812,"eighty":14.074073,"marketCap":78600000},{"date":"2024-04-05","current":7.138968,"twenty":7.941228,"median":9.862382,"eighty":14.074635,"marketCap":82440000},{"date":"2024-04-12","current":6.910355,"twenty":7.889973,"median":9.862382,"eighty":14.074635,"marketCap":79800000},{"date":"2024-04-19","current":6.827222,"twenty":7.844425,"median":9.862382,"eighty":14.074635,"marketCap":78840000},{"date":"2024-04-26","current":7.502671,"twenty":7.795306,"median":9.855812,"eighty":14.074073,"marketCap":86640000},{"date":"2024-05-03","current":6.894767,"twenty":7.726926,"median":9.855812,"eighty":14.074073,"marketCap":79620000},{"date":"2024-05-10","current":7.149359,"twenty":7.682222,"median":9.855812,"eighty":14.074073,"marketCap":82560000},{"date":"2024-05-17","current":8.966269,"twenty":7.640335,"median":9.83829,"eighty":14.074073,"marketCap":84300000},{"date":"2024-05-24","current":8.729508,"twenty":7.640335,"median":9.831805,"eighty":14.074073,"marketCap":82074000},{"date":"2024-05-31","current":9.135384,"twenty":7.640335,"median":9.831805,"eighty":14.074073,"marketCap":85890000},{"date":"2024-06-07","current":8.570604,"twenty":7.640335,"median":9.831805,"eighty":14.074073,"marketCap":80580000},{"date":"2024-06-14","current":8.398299,"twenty":7.638623,"median":9.834885,"eighty":14.074635,"marketCap":78960000},{"date":"2024-06-21","current":6.892221,"twenty":7.624059,"median":9.837965,"eighty":14.075197,"marketCap":64800000},{"date":"2024-06-28","current":6.707152,"twenty":7.615202,"median":9.831072,"eighty":14.076884,"marketCap":63060000},{"date":"2024-07-05","current":6.209381,"twenty":7.583787,"median":9.797365,"eighty":14.076884,"marketCap":58380000},{"date":"2024-07-12","current":6.05622,"twenty":7.549432,"median":9.790107,"eighty":14.076884,"marketCap":56940000},{"date":"2024-07-15","current":6.566755,"twenty":7.541516,"median":9.790107,"eighty":14.076884,"marketCap":61740000},{"date":"2024-08-02","current":6.483793,"twenty":7.526694,"median":9.849614,"eighty":14.097348,"marketCap":60960000},{"date":"2024-08-09","current":6.362541,"twenty":7.500185,"median":9.849614,"eighty":14.097348,"marketCap":59820000},{"date":"2024-08-16","current":8.330038,"twenty":7.484922,"median":9.849614,"eighty":14.097348,"marketCap":64200000},{"date":"2024-08-23","current":7.921321,"twenty":7.484922,"median":9.849614,"eighty":14.097348,"marketCap":61050000},{"date":"2024-08-30","current":7.699446,"twenty":7.484922,"median":9.849614,"eighty":14.097348,"marketCap":59340000},{"date":"2024-09-06","current":7.119457,"twenty":7.435611,"median":9.849614,"eighty":14.097348,"marketCap":54870000},{"date":"2024-09-13","current":7.15449,"twenty":7.407031,"median":9.849614,"eighty":14.097348,"marketCap":55140000},{"date":"2024-09-20","current":7.240126,"twenty":7.361001,"median":9.849614,"eighty":14.097348,"marketCap":55800000},{"date":"2024-09-27","current":8.080915,"twenty":7.361001,"median":9.849614,"eighty":14.097348,"marketCap":62280000},{"date":"2024-10-04","current":8.392318,"twenty":7.407031,"median":9.849614,"eighty":14.097348,"marketCap":64680000},{"date":"2024-10-11","current":8.115948,"twenty":7.435611,"median":9.849614,"eighty":14.097348,"marketCap":62550000},{"date":"2024-10-18","current":8.610301,"twenty":7.490676,"median":9.849614,"eighty":14.097348,"marketCap":66360000},{"date":"2024-10-25","current":8.485739,"twenty":7.521459,"median":9.849614,"eighty":14.097348,"marketCap":65400000},{"date":"2024-10-31","current":8.174336,"twenty":7.534577,"median":9.849614,"eighty":14.097348,"marketCap":63000000},{"date":"2024-11-08","current":7.715016,"twenty":7.56266,"median":9.849614,"eighty":14.098591,"marketCap":59460000},{"date":"2024-11-15","current":8.879894,"twenty":7.56266,"median":9.849614,"eighty":14.098591,"marketCap":60180000},{"date":"2024-11-22","current":9.827201,"twenty":7.56266,"median":9.849614,"eighty":14.098591,"marketCap":66600000},{"date":"2024-11-29","current":9.685547,"twenty":7.56266,"median":9.849614,"eighty":14.098591,"marketCap":65640000},{"date":"2024-12-06","current":8.959574,"twenty":7.56266,"median":9.849614,"eighty":14.098591,"marketCap":60720000},{"date":"2024-12-13","current":8.986134,"twenty":7.586268,"median":9.849614,"eighty":14.098591,"marketCap":60900000},{"date":"2024-12-20","current":8.277867,"twenty":7.640637,"median":9.849614,"eighty":14.098591,"marketCap":56100000},{"date":"2024-12-27","current":8.764801,"twenty":7.70256,"median":9.849614,"eighty":14.098591,"marketCap":59400000},{"date":"2025-01-03","current":8.844481,"twenty":7.70256,"median":9.849614,"eighty":14.098591,"marketCap":59940000},{"date":"2025-01-10","current":8.729387,"twenty":7.699446,"median":9.849614,"eighty":14.099834,"marketCap":59160000},{"date":"2025-01-17","current":9.145494,"twenty":7.699446,"median":9.849614,"eighty":14.099834,"marketCap":61980000},{"date":"2025-01-24","current":9.836054,"twenty":7.699446,"median":9.849614,"eighty":14.099834,"marketCap":66660000},{"date":"2025-01-31","current":9.473067,"twenty":7.699446,"median":9.849614,"eighty":14.099834,"marketCap":64200000},{"date":"2025-02-07","current":9.402241,"twenty":7.715016,"median":9.849614,"eighty":14.099834,"marketCap":63720000},{"date":"2025-02-14","current":9.366827,"twenty":7.715016,"median":9.849614,"eighty":14.099834,"marketCap":63480000},{"date":"2025-02-21","current":9.729814,"twenty":7.715016,"median":9.855812,"eighty":14.099834,"marketCap":65940000},{"date":"2025-02-28","current":9.579307,"twenty":7.715016,"median":9.855812,"eighty":14.099834,"marketCap":64920000},{"date":"2025-03-07","current":9.437654,"twenty":7.811551,"median":9.862382,"eighty":14.103137,"marketCap":63960000},{"date":"2025-03-14","current":9.517334,"twenty":7.856705,"median":9.862382,"eighty":14.103137,"marketCap":64500000},{"date":"2025-03-21","current":9.836054,"twenty":7.920558,"median":9.862382,"eighty":14.103137,"marketCap":66660000},{"date":"2025-03-28","current":12.427309,"twenty":7.995093,"median":9.897835,"eighty":14.103137,"marketCap":70560000},{"date":"2025-04-04","current":12.532984,"twenty":8.041719,"median":9.940527,"eighty":14.103137,"marketCap":71160000},{"date":"2025-04-11","current":10.778789,"twenty":8.097564,"median":9.977707,"eighty":14.099834,"marketCap":61200000},{"date":"2025-04-17","current":11.465672,"twenty":8.121938,"median":10.010072,"eighty":14.099834,"marketCap":65100000},{"date":"2025-04-25","current":10.736519,"twenty":8.165725,"median":10.052751,"eighty":14.103137,"marketCap":60960000}],"updateTime":1745837769561}}}